Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DBPV74
|
|||
| Drug Name |
BP1002
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Haematopoietic/lymphoid cancer [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | |
| Company |
Bio-Path Holdings
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04072458) A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Bio-Path Holdings. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.